elenestinib   Click here for help

GtoPdb Ligand ID: 12357

Synonyms: BLU-263 | BLU263 | exampl4 4 [WO2020210293A1]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Elenestinib (BLU-263) is a KIT inhibitor that is being developed for potential to treat systemic mastocytosis [1]. It is designed to show selectivity for the gain-of-function mutant KITD816V. Elenestinib has limited ability to cross the blood-brain-barrier (lower penetration capacity than the approved inhibitor avapritinib), so is expected to have a lower risk of central nervous system toxicity.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 126.52
Molecular weight 528.25
XLogP 3.5
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OCCn1ncc(c1)c1cn2c(c1)c(ncn2)N1CCN(CC1)c1ncc(cn1)[C@](c1ccc(cc1)F)(N)C
Isomeric SMILES C[C@](c1ccc(cc1)F)(c1cnc(nc1)N1CCN(CC1)c1ncnn2c1cc(c2)c1cn(nc1)CCO)N
InChI InChI=1S/C27H29FN10O/c1-27(29,21-2-4-23(28)5-3-21)22-14-30-26(31-15-22)36-8-6-35(7-9-36)25-24-12-19(17-38(24)34-18-32-25)20-13-33-37(16-20)10-11-39/h2-5,12-18,39H,6-11,29H2,1H3/t27-/m0/s1
InChI Key IPMARPMXSFFZFG-MHZLTWQESA-N
Immunopharmacology Comments
Gain-of-function mutant KIT proteins (such as D816V) are known to drives disease pathogenesis in systemic mastocytosis (SM). Inhibition of KIT signalling is a proven therapeutic approach for SM, with the approval of avapritinib in 2020 [1].